Drug Discovery

The traditional classification of cancer based primarily on the organ where a tumor first appears is rapidly being superseded by a sophisticated genomic perspective that prioritizes the specific molecular drivers of the disease. Recent breakthroughs led by Dr. Derya Deniz Özdemir and an

Huntington’s disease remains one of the most devastating neurological conditions known to modern medicine, characterized by a relentless decline in both motor control and cognitive function that eventually strips patients of their independence and identity. This genetic disorder stems from a

The 2026 American Association for Cancer Research annual meeting in San Diego stands as a definitive proving ground where South Korean biotechnology firms must transition from theoretical promise to clinical validation. Unlike later-stage conferences such as ASCO or ESMO, the AACR provides a unique

The complexity of biological systems often leaves pharmaceutical researchers grappling with a vast "dark matter" of untreatable conditions, where nearly 90% of human biology remains untouched by current therapeutic interventions. This systemic limitation has historically led to a high-risk and

While Chimeric Antigen Receptor (CAR) T-cell therapy has successfully transformed the clinical outlook for patients with liquid cancers, its efficacy against solid tumors remains one of the most significant hurdles in modern oncology. Unlike the accessible environment of the bloodstream, where

The pharmaceutical landscape is currently witnessing a high-stakes confrontation as Shanghai Henlius Biotech maneuvers to intercept Pfizer’s dominance in the next generation of lung cancer therapy. At the heart of this struggle is the development of antibody-drug conjugates (ADCs) targeting PD-L1,